GenSight Biologics reports topline results at Week 48 of the RESCUE Phase III clinical trial of GS010 in subjects within six months of visual loss onset due to Leber Hereditary Optic Neuropathy (LHON)

ARVO Annual Meeting, Vancouver, BC, Canada

GenSight Biologics reports sustained quality of life improvements at Week 72 of Phase III REVERSE clinical trial of GS010 for the treatment of Leber Hereditary Optic Neuropathy (LHON)

45th NANOS Annual Meeting, Las Vegas, Nevada, US

World Orphan Drug Congress Europe, Barcelona, Spain

GenSight Biologics reports positive 72-week data from REVERSE Phase III clinical trial of GS010 for the treatment of Leber Hereditary Optic Neuropathy (LHON)

GenSight Biologics to present REVERSE data with GS010 at the 2018 Annual Meeting of the American Academy of Ophthalmology

GenSight Biologics provides an update on the clinical and regulatory pathways for GS010

Ophthalmology Innovation Summit @ AAO, Chicago (IL)

American Academy of Ophthalmology, Chicago (IL)